Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317455 · ClinicalTrials.gov registry record · Early Phase 1
Regulation of Brain Glucose Metabolism in Type 1 Diabetes
A Early Phase 1 study of Diabetes Mellitus, Type 1 and Hypoglycemia Unawareness, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05317455: Recruiting Early Phase 1 study of Diabetes Mellitus, Type 1 and Hypoglycemia Unawareness, sponsored by Yale University.
NCT05317455 is a Early Phase 1 study of Diabetes Mellitus, Type 1 and Hypoglycemia Unawareness that is actively recruiting participants, run by Yale University. The registered enrollment target is 16 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05317455, a Early Phase 1 study of Diabetes Mellitus, Type 1 and Hypoglycemia Unawareness, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective randomized placebo-controlled double-blind crossover pilot study determining the effect of dichloroacetate on brain function under clamped hypoglycemia in T1DM.
Primary Outcome
Measures of reaction time \[in milliseconds\] and cognitive testing performance under hypoglycemia \[percentage\].
Conditions Studied
Interventions
- DRUG Dichloroacetate
Study Locations (1)
Connecticut
- Yale-New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2026-06-30 |
| Phase | Early Phase 1 |
What NCT05317455 shows while recruiting
NCT05317455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Dichloroacetate is the first listed.
NCT05317455 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05317455 about?
NCT05317455 is a clinical study titled "Regulation of Brain Glucose Metabolism in Type 1 Diabetes". This is a prospective randomized placebo-controlled double-blind crossover pilot study determining the effect of dichloroacetate on brain function under clamped hypoglycemia in T1DM.
What is the current status of trial NCT05317455?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2025-05-13. Estimated completion is 2026-06-30.
What conditions does trial NCT05317455 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1, Hypoglycemia Unawareness.
What interventions are being tested in trial NCT05317455?
The interventions under investigation include: Dichloroacetate (DRUG).
Who is sponsoring clinical trial NCT05317455?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05317455 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05317455's enrollment target sits among peer trials
16 106th of 118 higher than 13 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CBTi for the Treatment of Insomnia in Type 1 Diabetes
RECRUITING · Early Phase 1
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Genetics Of Autoimmunity In Type I Diabetes
RECRUITING
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI